ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2014

Effect of a Whole Food Plant-Based Diet in Patients with Gout: A Pilot Randomized Controlled Trial

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 1885

Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2040

Effective Management of Idiopathic Recurrent Pericarditis with Anakinra in Clinical Practice

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2034

Effectiveness and Tolerability of Tocilizumab in Systemic Autoimmune Rheumatic Disease Associated Intertistial Lung Disease

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2445

Effects of Aminaphtone on TGF-beta1 Serum Concentration as Concomitant Treatment to Standard Therapy in Systemic Sclerosis Patients: A Pilot Study

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2259

Effects of Anti-Obesity Medications in RA Patients

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1932

Effects of Clinical Decision Support on Transition Readiness Assessment in Pediatric Rheumatology

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2353

Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1999

Effects of JAK Inhibitors on Subsets of the Innate Immune System

Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 2084

Efficacy and Safety of a Step-down Regimen of Low Dosage of Glucocorticoids Combined with Early Administration of Synthetic or Biologic Immunosuppressants in Anti-synthetase Syndrome: A Pilot Study

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2483

Efficacy and Safety of Avacopan over 12 Months in Japanese Patients with MPA/GPA: A Single-center Study

Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 1980

Efficacy and Safety of Methotrexate in Immune Checkpoint Inhibitor-induced Arthritis: A Retrospective Longitudinal Monocentric Study

Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 2274

Efficacy and Safety of the Biased Melanocortin Receptor Agonist AP1189/resomelagon in Combination with Methotrexate in DMARD-naïve Rheumatoid Arthritis Patients: The EXPAND Trial

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: L09

Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis

(L01–L14) Late-Breaking Posters

10:30AM-12:30PM: Abstract Number: 2355

Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials

SpA Including PsA – Treatment Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].